Compare TXMD & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXMD | BCTX |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 28.8M |
| IPO Year | 2012 | 2025 |
| Metric | TXMD | BCTX |
|---|---|---|
| Price | $1.98 | $4.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 22.6K | ★ 135.7K |
| Earning Date | 05-12-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.68 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,761,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 35.25 | N/A |
| 52 Week Low | $0.98 | $0.61 |
| 52 Week High | $2.95 | $14.68 |
| Indicator | TXMD | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.25 | 49.41 |
| Support Level | $1.94 | $4.10 |
| Resistance Level | $2.05 | $4.56 |
| Average True Range (ATR) | 0.12 | 0.18 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 12.50 | 70.00 |
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.